Ask AI
MANIFEST 2
MANIFEST-2 Update: Phase III Trial of Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

Released: June 05, 2024

Activity

Progress
1
Course Completed